Lipigon is a project portfolio company currently managing three active drug projects, with Lipisense® being the most advanced.

• Project 1 (P1): Lipisense®
  An RNA drug targeting elevated triglycerides.

• Project 2 (P2): Lipodystrophi
  A gene therapy project for the rare disease lipodystrophy. Project in collaboration with Combigene AB (publ).

• Project 3 (P3): Dyslipidemia
  A small molecule project for dyslipidemia (general lipid disorders). Project in partnership with HitGen, Inc.

• Project 4 (P4): CAP
  An RNA drug project for Community-Acquired Pneumonia (CAP).

See the full pipeline